NextCure, Inc. Share Price
NXTCNextCure, Inc. Stock Performance
Open $11.55 | Prev. Close $10.95 | Circuit Range N/A |
Day Range $11.55 - $11.85 | Year Range $0.22 - $15.61 | Volume 320 |
Average Traded $11.70 |
NextCure, Inc. Share Price Chart
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
NextCure, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
07-Apr-26 | $10.95 | $10.95 | -2.71% |
06-Apr-26 | $11.05 | $11.26 | -0.22% |
01-Apr-26 | $11.28 | $11.28 | +8.10% |
31-Mar-26 | $10.44 | $10.44 | +8.47% |
30-Mar-26 | $10.38 | $9.62 | -4.28% |
27-Mar-26 | $10.70 | $10.05 | -0.15% |
24-Mar-26 | $10.30 | $10.06 | -8.25% |